Sifan Lu, Eileen Rakovitch, Breffni Hannon, Camilla Zimmermann, Kavita V Dharmarajan, Michael Yan, John R De Almeida, Christopher M K L Yao, Erin F Gillespie, Fumiko Chino, Divya Yerramilli, Ethan Goonaratne, Fadwa Abdel-Rahman, Hiba Othman, Sara Mheid, Chiaojung Jillian Tsai
{"title":"Palliative Care as a Component of High-Value and Cost-Saving Care During Hospitalization for Metastatic Cancer.","authors":"Sifan Lu, Eileen Rakovitch, Breffni Hannon, Camilla Zimmermann, Kavita V Dharmarajan, Michael Yan, John R De Almeida, Christopher M K L Yao, Erin F Gillespie, Fumiko Chino, Divya Yerramilli, Ethan Goonaratne, Fadwa Abdel-Rahman, Hiba Othman, Sara Mheid, Chiaojung Jillian Tsai","doi":"10.1200/OP.23.00576","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Randomized controlled trials have demonstrated that palliative care (PC) can improve quality of life and survival for outpatients with advanced cancer, but there are limited population-based data on the value of inpatient PC. We assessed PC as a component of high-value care among a nationally representative sample of inpatients with metastatic cancer and identified hospitalization characteristics significantly associated with high costs.</p><p><strong>Methods: </strong>Hospitalizations of patients 18 years and older with a primary diagnosis of metastatic cancer from the National Inpatient Sample from 2010 to 2019 were analyzed. We used multivariable mixed-effects logistic regression to assess medical services, patient demographics, and hospital characteristics associated with higher charges billed to insurance and hospital costs. Generalized linear mixed-effects models were used to determine cost savings associated with provision of PC.</p><p><strong>Results: </strong>Among 397,691 hospitalizations from 2010 to 2019, the median charge per admission increased by 24.9%, from $44,904 in US dollars (USD) to $56,098 USD, whereas the median hospital cost remained stable at $14,300 USD. Receipt of inpatient PC was associated with significantly lower charges (odds ratio [OR], 0.62 [95% CI, 0.61 to 0.64]; <i>P</i> < .001) and costs (OR, 0.59 [95% CI, 0.58 to 0.61]; <i>P</i> < .001). Factors associated with high charges were receipt of invasive medical ventilation (<i>P</i> < .001) or systemic therapy (<i>P</i> < .001), Hispanic patients (<i>P</i> < .001), young age (18-49 years, <i>P</i> < .001), and for-profit hospitals (<i>P</i> < .001). PC provision was associated with a $1,310 USD (-13.6%, <i>P</i> < .001) reduction in costs per hospitalization compared with no PC, independent of the receipt of invasive care and age.</p><p><strong>Conclusion: </strong>Inpatient PC is associated with reduced hospital costs for patients with metastatic cancer, irrespective of age and receipt of aggressive interventions. Integration of inpatient PC may de-escalate costs incurred through low-value inpatient interventions.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"252-260"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO oncology practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/OP.23.00576","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Randomized controlled trials have demonstrated that palliative care (PC) can improve quality of life and survival for outpatients with advanced cancer, but there are limited population-based data on the value of inpatient PC. We assessed PC as a component of high-value care among a nationally representative sample of inpatients with metastatic cancer and identified hospitalization characteristics significantly associated with high costs.
Methods: Hospitalizations of patients 18 years and older with a primary diagnosis of metastatic cancer from the National Inpatient Sample from 2010 to 2019 were analyzed. We used multivariable mixed-effects logistic regression to assess medical services, patient demographics, and hospital characteristics associated with higher charges billed to insurance and hospital costs. Generalized linear mixed-effects models were used to determine cost savings associated with provision of PC.
Results: Among 397,691 hospitalizations from 2010 to 2019, the median charge per admission increased by 24.9%, from $44,904 in US dollars (USD) to $56,098 USD, whereas the median hospital cost remained stable at $14,300 USD. Receipt of inpatient PC was associated with significantly lower charges (odds ratio [OR], 0.62 [95% CI, 0.61 to 0.64]; P < .001) and costs (OR, 0.59 [95% CI, 0.58 to 0.61]; P < .001). Factors associated with high charges were receipt of invasive medical ventilation (P < .001) or systemic therapy (P < .001), Hispanic patients (P < .001), young age (18-49 years, P < .001), and for-profit hospitals (P < .001). PC provision was associated with a $1,310 USD (-13.6%, P < .001) reduction in costs per hospitalization compared with no PC, independent of the receipt of invasive care and age.
Conclusion: Inpatient PC is associated with reduced hospital costs for patients with metastatic cancer, irrespective of age and receipt of aggressive interventions. Integration of inpatient PC may de-escalate costs incurred through low-value inpatient interventions.